Lisa M Kattenhorn

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Systemically delivered adeno-associated viral (AAV) vectors are now in early-phase clinical trials for a variety of diseases. While there is a general consensus on inclusion and exclusion criteria for each of these trials, the conditions under which vectors are infused vary significantly. In this study, we evaluated the impact of intravenous infusion rate(More)
  • 1